Current and historical daily PE Ratio for Formycon AG (
XTER:FYB
) from 2010 to May 15 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Formycon AG stock (XTER:FYB) PE ratio as of May 15 2024 is 9.24.
More Details
Formycon AG (XTER:FYB) PE Ratio (TTM) Chart
Formycon AG (XTER:FYB) PE Ratio (TTM) Historical Data
View and export this data going back to 2010. Start your Free Trial
Total 1238
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Formycon AG PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-16 | 9.2 | 2024-03-08 | 10.1 |
| 2024-05-14 | 9.2 | 2024-03-07 | 10.5 |
| 2024-05-13 | 9.1 | 2024-03-06 | 10.2 |
| 2024-05-10 | 9.1 | 2024-03-05 | 9.9 |
| 2024-05-09 | 9.1 | 2024-03-04 | 10.0 |
| 2024-05-08 | 9.0 | 2024-03-01 | 10.3 |
| 2024-05-07 | 9.5 | 2024-02-29 | 10.2 |
| 2024-05-06 | 9.8 | 2024-02-28 | 10.3 |
| 2024-05-03 | 9.2 | 2024-02-27 | 10.7 |
| 2024-05-02 | 8.7 | 2024-02-26 | 10.6 |
| 2024-04-30 | 8.7 | 2024-02-23 | 10.7 |
| 2024-04-29 | 8.8 | 2024-02-22 | 11.4 |
| 2024-04-26 | 8.5 | 2024-02-21 | 11.6 |
| 2024-04-25 | 8.4 | 2024-02-20 | 11.3 |
| 2024-04-24 | 8.3 | 2024-02-19 | 11.7 |
| 2024-04-23 | 8.3 | 2024-02-16 | 11.7 |
| 2024-04-22 | 8.1 | 2024-02-15 | 11.8 |
| 2024-04-19 | 8.2 | 2024-02-14 | 11.6 |
| 2024-04-18 | 8.4 | 2024-02-13 | 11.3 |
| 2024-04-17 | 8.5 | 2024-02-12 | 11.1 |
| 2024-04-16 | 9.1 | 2024-02-09 | 10.8 |
| 2024-04-15 | 9.6 | 2024-02-08 | 10.8 |
| 2024-04-12 | 9.8 | 2024-02-07 | 10.4 |
| 2024-04-11 | 9.8 | 2024-02-06 | 10.2 |
| 2024-04-10 | 9.7 | 2024-02-05 | 9.9 |
| 2024-04-09 | 9.8 | 2024-02-02 | 10.2 |
| 2024-04-08 | 9.7 | 2024-02-01 | 10.3 |
| 2024-04-05 | 9.8 | 2024-01-31 | 10.7 |
| 2024-04-04 | 9.8 | 2024-01-30 | 10.9 |
| 2024-04-03 | 9.7 | 2024-01-29 | 10.7 |
| 2024-04-02 | 9.6 | 2024-01-26 | 10.5 |
| 2024-03-28 | 9.8 | 2024-01-25 | 10.4 |
| 2024-03-27 | 9.8 | 2024-01-24 | 10.5 |
| 2024-03-26 | 9.6 | 2024-01-23 | 10.4 |
| 2024-03-25 | 9.6 | 2024-01-22 | 10.3 |
| 2024-03-22 | 10.0 | 2024-01-19 | 10.2 |
| 2024-03-21 | 9.8 | 2024-01-18 | 10.3 |
| 2024-03-20 | 9.8 | 2024-01-17 | 9.8 |
| 2024-03-19 | 9.5 | 2024-01-16 | 10.4 |
| 2024-03-18 | 9.7 | 2024-01-12 | 11.1 |
| 2024-03-15 | 9.6 | 2024-01-11 | 10.9 |
| 2024-03-14 | 9.7 | 2024-01-10 | 11.2 |
| 2024-03-13 | 9.9 | 2024-01-09 | 11.2 |
| 2024-03-12 | 10.2 | 2024-01-08 | 11.3 |
| 2024-03-11 | 10.2 | 2024-01-05 | 11.2 |
Formycon AG (XTER:FYB) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Formycon AG
ISIN : DE000A1EWVY8
Compare
Compare
Traded in other countries / regions
FYB.Germany0W4N.UK IPO Date
2010-12-20Description
Formycon AG is a pharmaceutical company. It is engaged in the development of pharmaceutical and biopharmaceutical products and the development of drug delivery systems. Its focus is on treatments in ophthalmology and immunology as well as other chronic diseases. The company's pipeline in the biosimilar drugs category includes FYB201, FYB202, FYB203, and FYB207 for the treatment of COVID-19. It is also engaged in the provision of diagnostic laboratory services and works for third parties and the carrying out of diagnostic laboratory services.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers